MDT-AP-2651
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 3
- sex
- M
- new_clusters
- C1
- umap1_2d
- 3.812189845
- umap2_2d
- 1.034277911
- umap1_3d
- 0.447244915
- umap2_3d
- -2.069694626
- umap3_3d
- -0.848707296
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.660
- INFLAMMATORY_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.600
- IL6_JAK_STAT3_SIGNALING+0.580
- ANGIOGENESIS+0.530
- KRAS_SIGNALING_UP+0.520
- COMPLEMENT+0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- INTERFERON_GAMMA_RESPONSE+0.490
- COAGULATION+0.460
Top 10 suppressed
- MYC_TARGETS_V2-0.360
- DNA_REPAIR-0.300
- E2F_TARGETS-0.220
- MITOTIC_SPINDLE-0.220
- MYC_TARGETS_V1-0.200
- HEDGEHOG_SIGNALING-0.190
- G2M_CHECKPOINT-0.160
- OXIDATIVE_PHOSPHORYLATION-0.080
- PROTEIN_SECRETION-0.080
- PI3K_AKT_MTOR_SIGNALING-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0355 | Med | Medulloblastoma | 0.928 |
| 2 | ERR2208908 | — | — | 0.921 |
| 3 | BS_769BDPDB | pilocytic astrocytoma | — | 0.918 |
| 4 | SRR33532823 | — | C | 0.916 |
| 5 | BS_YY5B2XDD | pilocytic astrocytoma | — | 0.916 |
| 6 | SRR10900576 | — | — | 0.908 |
| 7 | BS_THSPSG2Z | Meningioma | — | 0.907 |
| 8 | ERR2598287 | fetal | fetal | 0.907 |
| 9 | MNG639 | — | — | 0.904 |
| 10 | BS_8VAZSJEN | pilocytic astrocytoma | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.660 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.630 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.520 | Inavolisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| COAGULATION | 0.460 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.440 | Idelalisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.360 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |